Home » Medical Devices

COVID-19 Impact on Abbott Laboratories Revenue and Operations (Medical Devices)

Abbott is a medical technology company which designs, develops, manufactures and markets a wide range of medical devices, diagnostics, nutritional and generic medicines products, headquartered in United States, with global manufacturing and sales reach. Abbott's product range includes Continuous Glucose Monitoring; Remote Heart-Failure Monitoring; Chronic-Pain Devices; Blood and Plasma Screening; Point-of-care Testing; Adult and Pediatric Nutrition and also serves in providing the solutions for the treatment of heart failure; heart valve disorders; diseases of the coronary artery and other heart related diseases. It also provides biologic solutions for the dental markets. The report, COVID-19 Impact on Abbott Laboratories Revenue and Operations (Medical Devices) presents a deep dive analysis into how Abbott Laboratories is placed to respond to the COVID-19 crisis, by examining its sector performance and competitiveness.


The report provides a comprehensive analysis of the impact of COVID-19 on Abbott Laboratories –

– It provides insights on Abbott Laboratories's exposure to the regions and businesses impacted by the COVID-19 outbreak.

– It offers an overview of the company’s revenue impact by region and market for 2020 due to the COVID-19 outbreak.

Key Highlights

Abbott reported third-quarter worldwide sales increased 9.6% with diagnostic sales increased 38.8% and medical devices sales increased 3.4%.

Molecular diagnostics saw 313.1% growth in its third quarter due to the launch of critical new tests for COVID-19: Abbott's laboratory-based molecular tests for COVID-19 on its m2000™ and Alinity™ m platforms. Rapid Diagnostics experienced a growth in sales by 83.2% because of the strong demand of the Abbott’s POC ID NOW COVID-19 molecular test. However, core laboratory diagnostics sales growth was negatively impacted by lower routine diagnostics testing volumes.

Due to the negative business impact of COVID-19, both cardiovascular and neuromodulation businesses were negatively impacted by reduced procedure volumes due to the pandemic. However, diabetes care grew 25.9% in the third quarter of 2020.

Reasons to Buy

An overview of how Abbott Laboratories will be affected by the COVID-19 pandemic.

Key Players

Abbott Laboratories

Table of Contents

Table of Contents

COVID-19 impact analysis on Abbott Laboratories – Key Findings

Abbott Laboratories. Key Facts

Geographic spread analysis – COVID-19 vs Abbott Laboratories. sales

The impact of COVID-19 on regional GDP per capita levels

Abbott Laboratories. exposure: revenues by region and market vs regional impact levels

Abbott Laboratories : revenue impact by region and market for 2020

Operational reactions from Abbott Laboratories? Indications from recruitment trends

Operational reactions from Abbotts’ Indications from US pricing trends

Contact us


Discounts available for multiple purchases.

+44 20 7947 2960

Join our mailing list

Saved reports